ArticleBMC nephrology2026
Association of pre-transplant pulmonary hypertension and post-transplant major adverse cardiovascular events in kidney transplant recipients: a retrospective study.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary hypertension (PH) frequently complicates end-stage kidney disease, contributing significantly to cardiovascular morbidity and mortality. Some of the pathophysiologic effects of PH may persist even after kidney transplantation (KT). We investigated the association between pre-transplant PH and long-term major adverse cardiovascular events (MACE) after KT.
methodsThis retrospective cohort study included 468 adult KT recipients from an academic medical center between January 2015 and January 2024. We excluded patients who did not follow up at our institution and those with no adequate pre-transplant assessment of pulmonary artery (PA) pressures. Patients were stratified based on the presence of pre-transplant PH, defined as PA systolic pressure > 35 mmHg on echocardiography or mean PA pressure > 20 mmHg via right heart catheterization. The primary outcome was the occurrence of MACE after KT, defined as cardiovascular death, nonfatal myocardial infarction, stroke, or hospitalization for heart failure. Kaplan-Meier cumulative incidence curves and Multivariable Cox proportional hazards models were used.
resultsOf the 468 recipients who qualified for the study, 86 (18.4%) had pre-transplant PH. Over a mean follow-up of 54.7 ± 28.4 months, 89 patients (19.0%) experienced MACE. The incidence of MACE was significantly higher in the PH group at one- (8.1 vs 2.9%, p = 0.03) and five-year (22.0 vs 11.0%, p = 0.01). After adjusting for age, sex, and relevant confounders, PH remained independently associated with MACE (HR 2.15; 95% CI 1.25-3.70; p = 0.01).
conclusionsIn this retrospective single-center study, pre-transplant PH was independently associated with an increased risk for MACE following KT. These findings highlight the importance of identifying PH in KT candidates. Enhanced cardiovascular risk surveillance may be warranted in this population.
trial registrationNot applicable as this is a retrospective cohort study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.